This study assessed serious clinical outcomes comparing glucagon‐like peptide 1 receptor agonists (GLP‐1‐RAs) with sodium glucose co‐transporter 2 inhibitors (SGLT2‐Is) in patients with type 2 diabetes (T2DM) and patients without diabetes using two chronic weight management (CWM) regimens. Here, SLC5A2 is linked to type 2 diabetes mellitus.